Piper Sandler analyst Joseph Catanzaro initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight rating and announces Price Target of $25.
Gainers
Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.